Articles related to Behavioral Health

A systematic review of 12 studies found that vortioxetine consistently improved depressive symptoms in adults aged 65 years and older with major depressive disorder, but evidence for cognitive benefits remained mixed and largely confined to selected cognitive domains.

Magnetoencephalography-based analysis of 263 patients with major depressive disorder identified five distinct brain connectivity profiles, each associated with differing symptom patterns, supporting the view that depression may encompass biologically heterogeneous subgroups rather than a single neurobiological condition.

In a longitudinal analysis of more than 167,000 children in Wales, maternal depression was associated with higher rates of special educational needs and neurodevelopmental disorders. Additional risk observed among antidepressant-exposed pregnancies remained difficult to separate from underlying depression severity.

Research examining cannabis and sexual function suggests possible associations with increased sexual frequency and orgasm satisfaction in some users, but findings remain inconsistent, largely observational, and influenced by dose, timing, formulation, and individual factors.

Experts reviewing available evidence suggest melatonin and magnesium may support sleep through different mechanisms, though benefits appear dependent on the underlying cause of sleep disturbance and overall evidence remains mixed, particularly for magnesium.

The FDA granted Breakthrough Therapy designation to DT120, an oral lysergide formulation under investigation for major depressive disorder, based on phase 3 findings suggesting rapid and sustained antidepressant effects, though the treatment remains investigational and unapproved.